State Biosimilar Bills Pose New Threat To Budding Industry

Law360, New York (February 1, 2013, 7:10 PM EST) -- Spurred by safety concerns from brand-name drugmakers, state legislators around the country are proposing to restrict patient access to generic versions of pricey biologic medicines, posing a threat to the fledgling biosimilars industry and potentially treading on federal regulators' turf.

The state-level regulation, which includes a host of limits on when and how pharmacies can dispense biosimilars, is emerging as the life sciences industry eagerly awaits new information on how the U.S. Food and Drug Administration will oversee introduction of generics competition into the $140 billion...
To view the full article, register now.